Evidence map›Paper›PMID 36621905›Full record

SynthesisJournal of comparative effectiveness research2023

A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer.

Himani Aggarwal, Kerigo Ndirangu, Katherine B Winfree, Catherine Elizabeth Muehlenbein, Emily Zhu, Vanita Tongbram, Howard Thom

Open access · diamondAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of comparative effectiveness research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Himani AggarwalEli Lilly & Company, 893 S Delaware Street Indianapolis, IN 46225, USA.
Kerigo NdiranguICON plc, New York, NY, USA.
Katherine B WinfreeEli Lilly & Company, 893 S Delaware Street Indianapolis, IN 46225, USA.
Catherine Elizabeth MuehlenbeinEli Lilly & Company, 893 S Delaware Street Indianapolis, IN 46225, USA.
Emily ZhuEli Lilly & Company, 893 S Delaware Street Indianapolis, IN 46225, USA.
Vanita TongbramICON plc, New York, NY, USA.
Howard ThomHealth Economics Bristol (HEB), Bristol Medical School, University of Bristol, 1-5 Whiteladies Road Clifton Bristol, BS8 1NU, United Kingdom.
Eli Lilly (United States) · USUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBayes TheoremDocetaxelHumansImmunotherapyPemetrexedPlatinumDocetaxelPemetrexedPlatinumimmunotherapynetwork meta-analysisnonsquamous NSCLCpembrolizumab

Identifiers

PMID36621905
PMCPMC10288959
OpenAlexW4313857758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.